Clinical Trial Update: Metabolomic Analysis of Systemic Sclerosis

View source ↗

Summary

The ClinicalTrials.gov update reports that the metabolomic analysis study of systemic sclerosis and related connective tissue diseases has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon
• Systemic Sclerosis
• Undifferentiated Connective Tissue Disease

Snippet

Sponsor: University Hospital, Strasbourg, France | Conditions: Scleroderma (Limited and Diffuse), Undifferentiated Connective Tissue Disease | Status: TERMINATED